Abstract. Background and aim oft he work In patìents with disseminated endometrial carcinoma, doxorubicin is used as a single agent or in combination therapy. We have carried out a phase II clinical trial of liposomal doxorubicin in first-line therapy of women with disseminated endometrial carcinoma. Methods: Betwecn September 2001 and May 2003, 22 patìents with histologically confirmed disseminated endometrial carci¬noma, were enrolled in this study. Eleven patìents had been previously treated with radiatìon, none of them had been treated with chemotherapy. Liposomal doxorubicin (40 mg/m2) was intravenously administered at 4 week intervals until toxicity or progression. Results: The most common adverse events were fatigue, ane¬mia, pain, and dermatologic toxicity (EPP). Eight patìents (36%) achieved a tumor regression (Complete response, CR 3; Partial response, PR 5), ten (46%) maintained stable disease, and four (18%) experienced in-creasing disease. Conclusion: Liposomal doxorubicin has a lower cardiologie toxicity than doxorubicin with a similar response rate in patients with disseminated endometrial carcinoma, (www.actabiomedica.it)
Liposomal doxorubicin: a phase II trial
BALBI, Giancarlo;
2007
Abstract
Abstract. Background and aim oft he work In patìents with disseminated endometrial carcinoma, doxorubicin is used as a single agent or in combination therapy. We have carried out a phase II clinical trial of liposomal doxorubicin in first-line therapy of women with disseminated endometrial carcinoma. Methods: Betwecn September 2001 and May 2003, 22 patìents with histologically confirmed disseminated endometrial carci¬noma, were enrolled in this study. Eleven patìents had been previously treated with radiatìon, none of them had been treated with chemotherapy. Liposomal doxorubicin (40 mg/m2) was intravenously administered at 4 week intervals until toxicity or progression. Results: The most common adverse events were fatigue, ane¬mia, pain, and dermatologic toxicity (EPP). Eight patìents (36%) achieved a tumor regression (Complete response, CR 3; Partial response, PR 5), ten (46%) maintained stable disease, and four (18%) experienced in-creasing disease. Conclusion: Liposomal doxorubicin has a lower cardiologie toxicity than doxorubicin with a similar response rate in patients with disseminated endometrial carcinoma, (www.actabiomedica.it)I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
